Krsnaa Diagnostics Limited · NSE:KRSNAA
Krsnaa Diagnostics — Q4 FY2025-26 Earnings Presentation
31 slides from Krsnaa Diagnostics's earnings presentation, May 25, 2026
Slide 1: Regulation 30 intimation letter to stock exchanges
Date: May 25, 2026 Ref. No.: KDL/SE/013/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051
Slide 2: Q4 FY2025-26 Result Presentation
Q4 FY2025-26 Result Presentation One of INDIA’S LARGEST Integrated Diagnostic Service Provider
Slide 3: Disclaimer
Disclaimer This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance.
Slide 4: Company overview and network at a glance
190 4,700+ 59 Mn+ 68 CT/ MRI Centres Tests in Patient Collection Centres FY25-26 Million+ Patients Served 331 In Last 5 Years 147 18 Pathology Labs States/UT Districts Presence Presence in India PAN India One of India’s largest NABH Krsnaa Diagnostics is one of the accredited tele-radiology fastest
Slide 5: Q4 FY26 Financial Performance
Q4 FY26 Financial Performance Particulars Q4 FY26 Q4 FY25 Growth Particulars Q4 FY26 Q4 FY25 Growth Revenue 1,926 1,861 4% EPS 12.8 6.3 103% EBIDTA 559 545 3% No. of Patient 4.8 4.7 1% Served EBIDTA Margin 29% 29% - NABL Accreditation 54 51 6% PAT 417 207 102% (Pathology lab) NABH Accreditation PAT
Slide 6: Q4 FY26 Network Update
Q4 FY26 – Network Update A total of 51 Centers and 1,167 collection centers were operationalized in FY25-26 CT Centre MRI Centre Tele- Radiology Centre Upon completion of our existing order book, we will have 41 1,515 143 149 37 1,501 200+ CT/MRI centres, Radiology cementing our position as one of A
Slide 7: FY25-26 Financial Performance
FY25-26 Financial Performance Particulars FY25-26 FY24-25 Growth Particulars FY25-26 FY24-25 Growth Revenue 7,728 7,172 8% EPS 30.9 23.6 31% EBIDTA 2,149 1,958 10% No. of Patient 19.8 19.2 3% Served EBIDTA Margin 28% 27% 69 bps NABL Accreditation 54 51 6% PAT 1,013 776 31% (Pathology lab) NABH Accre
Slide 8: Driving Excellence Through Quality
Driving Excellence Through Quality India’s 1st ACR Accredited Company India’s 1st CAP Accredited Lab India’s 1st NABH Accredited at Government Facility Tele-Radiology Hub Service Excellence Pioneers of Indian Diagnostic Industry © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 7
Slide 9: Driving Excellence Through Quality
Driving Excellence Through Quality 54 54 National Accreditation for Board of National Accreditation Board for testing's & Calibration Laboratories Hospitals & Healthcare Providers We are committed to delivering superior quality as our benchmark and proudly served ~4.8 mn patients in Q4 FY26, driven
Slide 10: Presence - PAN India
Presence - PAN India Well Diversified Regional Revenue Mix 12% 32% Q4 FY26 44% 12% West South North East India map for representation only, not to scale © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 9
Slide 11: Growth Influencer - Competitive Advantages
Growth Influencer- Competitive Advantages 147 → 290+ 190 → 200+ 24×7- 365 Days Labs CT / MRI Centers Operations 4,700+ Collection Centers → 5,000+ 1,400+ X-ray Centers Round-the-clock availability KEY DIFFERENTIATORS Affordable Diagnostics Best in Quality Protocols Top quality standards across all l
Slide 12: Growth Drivers
Growth Drivers POLICY TAILWINDSS 3.3% → 5% Long Tenure Captive Consumer Cost Leadership Healthcare GDP (by 2030) Predictable & Long-term Government OPD & IPD patients Cost Optimisation: Business outlook: attributed to: • Radiology avg tenure term • District Hospitals • Volume-driven economies of $1,
Slide 13: Our Pricing - Everyone Can Afford
Our Pricing - “Everyone Can Afford” % lower from Segment Test Competition 1 Competition 2 Competition 3 Krsnaa competitors Radiology CT Brain 4,500 4,500 3,500 880 (75)% Radiology MRI Brain 8,000 8,250 7,000 1,340 (81)% Pathology CBC 250 250 200 37 (82)% Pathology Blood Sugar 85 80 70 20 (71)% Patho
Slide 14: Patient Experience at Its Best
Patient Experience at Its Best
Slide 15: Growth Engine - Rajasthan Pathology
Growth Engine- Rajasthan Pathology Kishangarh, Mother Lab Alwar, Mother Lab Actual centre images © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 14
Slide 16: Growth Engine - Rajasthan Pathology
Growth Engine- Rajasthan Pathology Rawatsar, Hub Lab Sawai Madhopur, Mother Lab Actual centre images © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 15
Slide 17: Growth Engine - Rajasthan Pathology
Growth Engine- Rajasthan Pathology Actual centre images © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 16
Slide 18: ESG Initiatives
ESG Initiatives
Slide 19: ESG Initiatives
ESG Initiatives Solar system capable of generating 80 ~1,77,000+ hours Learning and development Using Biodegradable bags for KW of green energy programs for employees BMW Workflow digitization eliminated the Effluent treatment plants for ~23,000+ Lives touched monthly need for 10,000+ paper wastewat
Slide 20: Retail Summary
Retail Summary Retail Revenue ( INR Mn) Patient Count (Mn) Test Volume (Mn) 0.15 0.47 158 0.09 64 0.18 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Retail Revenue Contribution to Group Revenue Revenue Per Patient (INR) Q4 FY25 Q4 FY26 1,503 3% 8% 711 RPL RPL Krsnaa Krsnaa 97% 92% Q4 FY25 Q4 FY26
Slide 21: Retail Key Strength
Retail Key Strength Forward Growth Horizon: Scale | Awareness | Technology Pillar A: Scale & Modality Advantage Pillar B: Awareness Pillar C: AI-Enabled Diagnostics PPP-Based Ecosystem Aggregator & Platform Partnerships Technology as a Scale Multiplier PPP Infrastructure Leverage RPL on Health Platf
Slide 22: Retail Forward Growth Journey
Retail Forward Growth Journey RPL Retail Scale-Up: Six Growth Engines ENGINE 1 7 to 8 ENGINE 2 1,000+ ENGINE 3 ~10-15% States Retail Centres Contribution to Tapping Preventive & Wellness Retail Revenue Strategic Expansion- Newer Building Depth in Space- Smart Report for Patient Geographies Existing
Slide 23: Activities in Retail Business
Activities in Retail Business Doctor Engagement Activities © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 22
Slide 24: Activities in Retail Business
Activities in Retail Business Health Checkup Camp/Awareness Programs © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 23
Slide 25: Activities in Retail Business
Activities in Retail Business Medical Conferences © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 24
Slide 26: Activities in Retail Business
Activities in Retail Business Center Branding © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 25
Slide 27: Financial Performance
DIAGNOSTICS Financial Performance 0 ©)
Slide 28: Consolidated Financial Performance
Consolidated Financial Performance In INR Mn Particulars Q4 FY 26 Q4 FY 25 Q3 FY 26 FY 26 FY 25 Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,926 1,861 1,812 7,728 7,172 Expenses Cost of Material Consumed 444 23% 415 22% 391 22% 1,790 23% 1,693 24% Employee benefits expense
Slide 29: Consolidated Financial Performance - Balance Sheet
Consolidated Financial Performance (INR In Mn) Assets Mar 31, 2026 Mar 31, 2025 Liabilities Mar 31, 2026 Mar 31, 2025 Non-current assets Equity Equity share capital 162.19 161.45 Property, plant and equipment 6,516.27 6,674.34 Other equity 9,641.69 8,666.25 Capital work-in-progress 2,080.72 29.63 To
Slide 30: Contact Information
Contact Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic perfor
Slide 31: Krsnaa Diagnostics
For further information please contact Krsnaa Diagnostics Sujoy Bose, Head- Secretarial, Legal and Compliance investors@krsnaa.in Contact: +91 73910 40109 https://krsnaadiagnostics.com
Krsnaa Diagnostics — Q4 FY2025-26 Earnings Presentation on 6ix